241 related articles for article (PubMed ID: 32045273)
1. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
[No Abstract] [Full Text] [Related]
2. TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.
Deubelbeiss C; Kolios AGA; Anzengruber F; French LE; Yawalkar N; Kempf W; Kerl K; Meier B; Navarini AA
J Cutan Pathol; 2018 Jan; 45(1):23-28. PubMed ID: 29023827
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
5. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
[No Abstract] [Full Text] [Related]
6. A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report.
Dastoli S; Iannone LF; Bennardo L; Silvestri M; Palleria C; Nisticò SP; De Sarro G; Russo E
Curr Drug Saf; 2020; 15(1):69-72. PubMed ID: 31362662
[TBL] [Abstract][Full Text] [Related]
7. Atopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis.
Zundell MP; Gottlieb AB; Stanger R
J Drugs Dermatol; 2024 Feb; 23(2):97-99. PubMed ID: 38306127
[TBL] [Abstract][Full Text] [Related]
8. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis.
Cohen JN; Bowman S; Laszik ZG; North JP
J Am Acad Dermatol; 2020 Feb; 82(2):430-439. PubMed ID: 31859047
[TBL] [Abstract][Full Text] [Related]
10. A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris.
Yousif J; Al-Dehneem R; Kaskas N; Gottlieb AB
J Drugs Dermatol; 2023 Dec; 22(12):1225-1227. PubMed ID: 38051861
[TBL] [Abstract][Full Text] [Related]
11. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
[TBL] [Abstract][Full Text] [Related]
12. Bullous acral eruption related to secukinumab.
Blackcloud P; Dupuy E; Kang Y; Smart C; Hsiao J
Dermatol Online J; 2019 Jun; 25(6):. PubMed ID: 31329391
[TBL] [Abstract][Full Text] [Related]
13. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
14. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
15. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
Teraki Y; Takahashi A; Inoue Y; Takamura S
Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
[No Abstract] [Full Text] [Related]
16. A Case of Ixekizumab-induced Psoriasiform Eruption.
Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
[No Abstract] [Full Text] [Related]
17. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
18. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
Azevedo A; Torres T
Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
[TBL] [Abstract][Full Text] [Related]
19. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
Blauvelt A
Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
[TBL] [Abstract][Full Text] [Related]
20. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
